Literature DB >> 2921090

Tobramycin dosage recommendation in patients with cystic fibrosis.

R L Davis1, P Mendelman, B Ramsey, A L Smith.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2921090     DOI： 10.1007/BF01643502

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


× No keyword cloud information.
  7 in total

1.  Determination of human body surface area from height and weight.

Authors:  J SENDROY; L P CECCHINI
Journal:  J Appl Physiol       Date:  1954-07       Impact factor: 3.531

2.  Pharmacokinetics of tobramycin in cystic fibrosis.

Authors:  H B Kelly; R Menendez; L Fan; S Murphy
Journal:  J Pediatr       Date:  1982-02       Impact factor: 4.406

Review 3.  The pathogenesis and treatment of pulmonary infections in patients with cystic fibrosis.

Authors:  M I Marks
Journal:  J Pediatr       Date:  1981-02       Impact factor: 4.406

4.  Tobramycin treatment of pseudomonas aeruginosa infections in cystic fibrosis.

Authors:  G E Hoff; P O Schiotz; J Paulsen
Journal:  Scand J Infect Dis       Date:  1974

5.  Pharmacokinetics of gentamicin in children and adults.

Authors:  G R Siber; P Echeverria; A L Smith; J W Paisley; D H Smith
Journal:  J Infect Dis       Date:  1975-12       Impact factor: 5.226

6.  Radioenzymatic assays for aminoglycosides with kanamycin 6'-acetyltransferase.

Authors:  A Weber; A L Smith; K E Opheim
Journal:  J Clin Microbiol       Date:  1985-03       Impact factor: 5.948

7.  Dosing implications of altered gentamicin disposition in patients with cystic fibrosis.

Authors:  G L Kearns; B C Hilman; J T Wilson
Journal:  J Pediatr       Date:  1982-02       Impact factor: 4.406
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.